Tempus AI, Inc. (NASDAQ:TEM) Major Shareholder Bradley A. Keywell Sells 265,000 Shares

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 265,000 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the sale, the insider now directly owns 15,218,365 shares in the company, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Tempus AI Stock Up 1.2 %

Shares of TEM opened at $35.15 on Friday. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s 50 day moving average is $46.03 and its 200-day moving average is $47.10. Tempus AI, Inc. has a 12 month low of $22.89 and a 12 month high of $79.49.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Loop Capital dropped their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday. Bank of America increased their price target on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday. Wolfe Research initiated coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Stifel Nicolaus downgraded shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their target price for the stock from $45.00 to $65.00 in a report on Monday, November 11th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.36.

Institutional Trading of Tempus AI

A number of institutional investors have recently modified their holdings of the stock. First Horizon Advisors Inc. bought a new position in shares of Tempus AI in the third quarter worth $30,000. Geode Capital Management LLC increased its holdings in Tempus AI by 0.4% in the 3rd quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock valued at $7,537,000 after buying an additional 539 shares during the period. FNY Investment Advisers LLC acquired a new position in shares of Tempus AI in the 4th quarter valued at approximately $67,000. Vestor Capital LLC bought a new stake in shares of Tempus AI during the 3rd quarter worth approximately $153,000. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Tempus AI by 10.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock worth $1,686,000 after acquiring an additional 2,765 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.